drugset / Trial / NCT00524667

HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

NCT00524667

Non-randomizedSingle-groupOpen-labelTreatment

Summary

OBJECTIVES To investigate: * the mechanism of Valproic Acid (VPA)-induced apoptosis in B-CLL * the ability of VPA in combination with standard chemotherapy or new antitumor agents to induce a synergistic antitumor effect in chronic lymphocytic leukemia (CLL) cells * the clinical efficacy of VPA in previously treated CLL patients. This will be an example of a translational research study where the results of our laboratory studies will be applied to a clinical trial in the CLL clinic at CancerCare Manitoba.

Timeline

Start
2008-01
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludarabine Small molecule 40 mg/m2 Oral
Subject Valproic Acid Small molecule 15 mg/kg Oral